International collaborative actions and transparency to understand, diagnose, and develop therapies for rare diseases
| Autor: | Christine M. Cutillo, Kym M. Boycott, Lilian P.L. Lau, Christopher P. Austin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Open science Orphan Drug Production International Cooperation MEDLINE Information Dissemination Patient advocacy 03 medical and health sciences 0302 clinical medicine Rare Diseases Inventions Stakeholder Participation Research Support as Topic Humans Biomarkers & Diagnostic Imaging business.industry Public relations Transparency (behavior) Social Control Formal 030104 developmental biology Knowledge Commentary Molecular Medicine Personalized medicine Genetics Gene Therapy & Genetic Disease business 030217 neurology & neurosurgery Social control Rare disease |
| Zdroj: | EMBO Molecular Medicine |
| ISSN: | 1757-4684 1757-4676 |
| Popis: | Rare diseases, which affect over 350 million people worldwide and frequently go undiagnosed or misdiagnosed for years, suffer from sparse and dispersed medical knowledge leading to even rarer approved and effective therapeutic options for patients. A vast, unmet need for research and investment to advance diagnostic capabilities and therapeutic development must be confronted, despite the myriad of challenges faced. Several fundamental shifts are changing the landscape of rare diseases research and development, particularly with the application and extension of results to common diseases and the advancement of personalized medicine initiatives. Collaborative strategies that pool resources and knowledge are vital, including team science, research networks, novel funding models, shared knowledge platforms, and innovative regulatory frameworks. Importantly, patients are also increasingly involved as research partners and funders, pushing for open science and transparency, and breaking down data silos and geographical borders, often enabled by online platforms accessible from across the globe. The International Rare Diseases Research Consortium (IRDiRC), established in 2011, has been working diligently to unify stakeholders (e.g., funding bodies, companies, umbrella patient advocacy groups, researchers, and experts) to seek and drive solutions that aim to accelerate diagnosis and therapeutic development for rare diseases worldwide. Further and future advances will depend on continued collaborations and cooperation among stakeholders, working hand in hand with patients, and exponentially improving research and development efficiency. Critically, engagement with stakeholders from underrepresented populations and less‐developed countries must be prioritized, to enable all people living with a rare disease to receive an accurate diagnosis, care, and therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text